Compare Natera Inc. Common Stock (NTRA) vs Nucor Corporation (NUE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Nucor Corporation — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while Nucor Corporation trades at $257.14 (market cap $57.58B). The key difference: Natera Inc. Common Stock and Nucor Corporation are close in size by market cap, and Nucor Corporation pays a 0.88% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Nucor Corporation for 78 Days on average.
| NTRA | NUE | |
|---|---|---|
Market Cap | $57.03B | $57.58B |
Volume | 1,131,157 | 874,073 |
Sector | Health | Basic Materials |
52-Week High | $425.64 | $274.74 |
52-Week Low | $179.42 | $131.78 |
Typical Hold Time | 0 Days | 78 Days |
Enterprise Value | $56.18B | $61.99B |
Dividend Yield | — | 0.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Nucor (NUE) trades at $257.11, up 2.1% today, showing strong momentum with a 50% gain over six months. The stock is in a bullish technical trend, supported by recent earnings beats in Q1 and Q2 2026. Fundamentals reflect solid profitability with a 7.99% net margin and 13.52% ROE, though revenue has moderated from 2022 peaks. The company maintains a strong balance sheet with a debt-to-asset ratio of 20.23% and recently declared its 214th consecutive dividend.
Outlook remains positive with analyst consensus at 'Buy' and a $266.88 price target, though near-term risks include competitive pressures from new steel capacity and volatility in steel prices. Earnings growth and operational efficiency are key catalysts, but investors should monitor Q3 2026 results against expectations of $5.80 EPS.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →
